The shedding usually stabilizes within a few weeks
GLOW is a three-peptide blend (GHK-Cu, BPC-157, TB-500)
Most patients begin with 2.5 mg once weekly for four weeks
Simple everyday activities like brushing teeth, touching the face, eating, drinking, talking, or shaving can trigger the pain
Side effects remain minimal when used appropriately
The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary